A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 10, 2019

Primary Completion Date

March 19, 2021

Study Completion Date

April 19, 2022

Conditions
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteRenal InsufficiencyLiver DiseaseNeoplasms
Interventions
DRUG

Azacitidine

Azacitidine subcutaneous or intravenous injection.

DRUG

Pevonedistat

Pevonedistat intravenous infusion.

Trial Locations (8)

8035

Hospital Universitario Vall d'Hebron - PPDS, Barcelona

8908

ICO lHospitalet Hospital Duran i Reynals, LHospitalet de Llobregat

10003

Hospital de San Pedro de Alcantara, Cáceres

10029

Icahn School of Medicine at Mount Sinai, New York

14004

C.H. Regional Reina Sofia, Córdoba

27514

University of North Carolina at Chapel Hill, Chapel Hill

37007

Complejo Asistencial Universitario de Salamanca H. Clinico, Salamanca

41013

Hospital Universitario Virgen del Rocio - PPDS, Seville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY